{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:42:43Z","timestamp":1770334963703,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T00:00:00Z","timestamp":1140566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p><jats:bold>Abstract: Background: <\/jats:bold> Post\u2010transplant lymphoproliferative disorders (PTLD) are potentially lethal complications of solid organ transplantation. We, here, report on our experience with rituximab, an anti\u2010CD20 monoclonal antibody, as first\u2010line treatment for PTLD in six lung transplant recipients.<\/jats:p><jats:p><jats:bold>Patients and methods: <\/jats:bold> Two of the patients developed PTLD during the first year after transplantation, while four developed late\u2010onset PTLD. One patient presented with PTLD localized to the graft, one had unilateral cervical lymph nodes, and the others presented with multi\u2010organ involvement. All patients had diffuse large B\u2010cell lymphoma. Immunosuppressive therapy was reduced and rituximab was administered at a dose of 375\u2003mg\/m<jats:sup>2<\/jats:sup>\/wk for 4\u2003wk.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> One patient did not respond to the first two courses of rituximab, received conventional chemotherapy, and achieved complete remission; four patients achieved complete remission after four courses with a median relapse\u2010free survival of 34 months (range: 14\u201355); and one patient did not respond and died. The diagnosis of complete remission was established by conventional imaging techniques combined to whole\u2010body positron emission tomography scan.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> We conclude that reduction in immunosuppression combined to first\u2010line treatment with rituximab may induce long\u2010term complete remission in lung transplant recipients presenting PTLD.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2005.00462.x","type":"journal-article","created":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T14:25:15Z","timestamp":1140618315000},"page":"179-187","source":"Crossref","is-referenced-by-count":36,"title":["Post\u2010transplant lymphoproliferative disorders after lung transplantation: first\u2010line treatment with rituximab may induce complete remission"],"prefix":"10.1111","volume":"20","author":[{"given":"Christiane","family":"Knoop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Kentos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Remmelink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Garbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Feremans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Estenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.03.015"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.5.1273"},{"key":"e_1_2_6_4_2","first-page":"1054","article-title":"Lymphoproliferative disease after lung transplantation","volume":"20","author":"Paranjothi S","year":"2001","journal-title":"comparison of presentation and outcome of early and late cases"},{"key":"e_1_2_6_5_2","first-page":"647","article-title":"Posttransplant lymphoproliferative disorders in lung transplant patients","volume":"15","author":"Ramalingam P","year":"2002","journal-title":"the Cleveland clinic experience"},{"key":"e_1_2_6_6_2","first-page":"505","article-title":"Post\u2010transplantation lymphoproliferative disease in heart and heart\u2010lung transplant recipients","volume":"22","author":"Gao SZ","year":"2003","journal-title":"30-yr experience at Stanford University"},{"key":"e_1_2_6_7_2","first-page":"1242","article-title":"Posttransplant lymphoproliferative disorder","volume":"124","author":"Reams BD","year":"2003","journal-title":"incidence, presentation, and response to treatment in lung transplant recipients"},{"key":"e_1_2_6_8_2","first-page":"956","article-title":"Registry of the International Society for Heart and Lung Transplantation","volume":"24","author":"Trulock EP","year":"2005","journal-title":"twenty-second Official Adult Lung and Heart-Lung Report \u2013 2005"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.6.8970360"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.4.9901013"},{"key":"e_1_2_6_11_2","first-page":"615","article-title":"Immunophenotypic variability of B\u2010cell non\u2010Hodgkin lymphoma","volume":"117","author":"Echeverri C","year":"2002","journal-title":"a retrospective study of cases analyzed by flow cytometry"},{"key":"e_1_2_6_12_2","first-page":"9","article-title":"Rituximab","volume":"27","author":"Grillo\u2010Lopez AJ.","year":"2000","journal-title":"an insider's historical perspective"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50025"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","unstructured":"McLaughlinP Grillo\u2010LopezAJ LinkBKet al.Rituximab chimeric anti\u2010CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four\u2010dose treatment program. J Clin Oncol1998:16:2825.","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_6_15_2","first-page":"3135","article-title":"Rituximab anti\u2010CD20 monoclonal antibody therapy in non\u2010Hodgkin's lymphoma","volume":"18","author":"Davis TA","year":"2000","journal-title":"safety and efficacy of retreatment"},{"key":"e_1_2_6_16_2","first-page":"803","article-title":"Rituximab","volume":"63","author":"Plosker GL","year":"2003","journal-title":"a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","unstructured":"KaleemZ HassanA PathanMH WhiteG.Flow cytometric evaluation of posttransplant B\u2010cell lymphoproliferative disorders. Arch Pathol Lab Med2004:128:181.","DOI":"10.5858\/2004-128-181-FCEOPB"},{"key":"e_1_2_6_18_2","first-page":"171","article-title":"CD\u201020 expression in post\u2010transplant lymphoproliferative disorders","volume":"65","author":"Ifthikharuddin JJ","year":"2000","journal-title":"treatment with rituximab"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02058-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(00)00087-5"},{"key":"e_1_2_6_21_2","first-page":"100","article-title":"Treatment of posttransplant lymphoproliferative disease with rituximab","volume":"73","author":"Verschuuren EA","year":"2002","journal-title":"the remission, the relapse, and the complication"},{"key":"e_1_2_6_22_2","first-page":"618","article-title":"Anti\u2010CD20 antibody (rituximab) administration in patients with late\u2010occurring lymphomas after solid organ transplantation","volume":"86","author":"Dotti G","year":"2001","journal-title":"Hematologica"},{"key":"e_1_2_6_23_2","first-page":"1076","article-title":"Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder","volume":"71","author":"Tsai DE","year":"2001","journal-title":"analysis of prognostic variables and long-term follow-up of 42 adult patients"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199911270-00015"},{"key":"e_1_2_6_25_2","first-page":"721","article-title":"Whole\u2010body positron emission tomography using fluorodeoxyglucose for staging of lymphoma","volume":"25","author":"Stumpe KD","year":"1998","journal-title":"effectiveness and comparison with computed tomography"},{"key":"e_1_2_6_26_2","first-page":"14","article-title":"Prognostic value of FDG\u2010PET in malignant lymphoma","volume":"47","author":"Becherer A","year":"2003","journal-title":"Q J Nucl Med"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2005.00462.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2005.00462.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:27:52Z","timestamp":1696912072000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2005.00462.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,22]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1399-0012.2005.00462.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2005.00462.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,22]]}}}